Athira Pharma, Inc.
ATHA
$0.2843
-$0.0197-6.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.65% | -21.08% | -18.69% | -2.57% | 2.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.86% | -6.31% | 11.92% | 24.51% | 35.18% |
| Operating Income | 23.86% | 6.31% | -11.92% | -24.51% | -35.18% |
| Income Before Tax | 17.62% | 9.38% | -5.30% | -13.38% | -23.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.62% | 9.38% | -5.30% | -13.38% | -23.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.62% | 9.38% | -5.30% | -13.38% | -23.04% |
| EBIT | 23.86% | 6.31% | -11.92% | -24.51% | -35.18% |
| EBITDA | 24.04% | 6.36% | -12.00% | -24.69% | -35.37% |
| EPS Basic | 18.55% | 10.26% | -4.47% | -12.51% | -22.13% |
| Normalized Basic EPS | 23.22% | 4.42% | -16.58% | -26.07% | -38.36% |
| EPS Diluted | 18.46% | 10.17% | -4.57% | -12.61% | -22.13% |
| Normalized Diluted EPS | 23.22% | 4.42% | -16.58% | -26.07% | -38.36% |
| Average Basic Shares Outstanding | 1.21% | 0.98% | 0.83% | 0.80% | 0.76% |
| Average Diluted Shares Outstanding | 1.21% | 0.98% | 0.83% | 0.80% | 0.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |